JNU-0921
JNU-0921 is a potent and orally active CD137 agonist. JNU-0921 increases the mRNA expression of IFN-γ and GZMB. JNU-0921 induces luciferase activity with an EC50 value of 64.07 nM.JNU-0921 enhances effector and memory function of cytotoxic CD8+ T cells (CTLs) and alleviates their exhaustion. JNU-0921 also skews polarization of helper T cells toward T helper 1 type and enhances their activity to boost CTL function. JNU-0921 shows anticancer activity[1].
Product Specifications
UNSPSC
12352005
Target
TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jnu-0921.html
Purity
99.77
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(O)C1=CC(C2=NOC(C3=CC(C=CC=C4)=C4C=C3)=N2)=CC=C1
Molecular Formula
C19H12N2O3
Molecular Weight
316.31
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
4E-BP1, phosphorylated (T69) (Eukaryotic Translation Initiation Factor 4E-Binding Protein 1, 4E-BP1, eIF4E-Binding Protein 1, Phosphorylated Heat- and acid-stable Protein Regulated by insulin 1, PHAS-I, EIF4EBP1, 4EBP1, PHAS I, PHASI) discontinued
4E-BP1, phosphorylated (T69) (Eukaryotic Translation Initiation Factor 4E-Binding Protein 1, 4E-BP1, eIF4E-Binding Protein 1, Phosphorylated Heat- and acid-stable Protein Regulated by insulin 1, PHAS-I, EIF4EBP1, 4EBP1, PHAS I, PHASI) discontinued
